Article
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2020
Schoenfeld A J, Rizvi H, Bandlamudi C, Sauter J L, Travis W D, Rekhtman N, Plodkowski A J, Perez-Johnston R, Sawan P, Beras A, Egger J V, Ladanyi M, Arbour K C, Rudin C M, Riely G J, Taylor B S, Donoghue M T A, Hellmann M D
Abstract excerpt
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular phenotype, clinical characteristics, and tumor features on PD-L1 expression is largely unknown and may improve prediction of response to ICI. PATIENTS AND METHODS: We evaluated...
Topics
- Adenocarcinoma of Lung
- B7-H1 Antigen
- High-Throughput Nucleotide Sequencing
- Humans
- Lung Neoplasms
- Mutation